1. 224PNeoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC). (23rd October 2018) Authors: Litton, J K; Moulder, S L; Hess, K R; Damodaran, S; Rauch, G M; Candelaria, R; Adrada, B E; Symmans, F; Murthy, R K; Helgason, T; Clayborn, A; Prabhakaran, S; Valero, V; Thompson, A M; Mittendorf, E A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗